Accelerate to discover
Related topics
Dec 1, 2022
Cytek Cloud is the new digital ecosystem that supports full spectrum flow cytometry research from panel design to data...
See More, Sort More with Cytek Full Spectrum Systems
Nov 28, 2022
Still wondering whether to join the shift to full spectrum cytometry? Easily transfer assays from your Cytek Northern...
Demonstrate the value of RareCyte Orion system via web-based Minerva viewer
Nov 25, 2022
The HTA CRC Atlas X dataset contains images and other data being used for construction of an atlas of human colorectal...
All inside your incubator: xCELLigence eSight
Nov 3, 2022
Multiplex Live cell imaging and real-time biosensor measurement with xCELLigence eSight
RareCyte Orion system advances Multi-modal digital pathology for colorectal cancer diagnosis
Oct 19, 2022
Precision medicine is critically dependent on better methods for diagnosing and staging disease and predicting drug...
Introducing MARS system : revolutionary solution for your workflow of cell separation and enrichment
Oct 7, 2022
The MARS family of instruments provides a breakthrough solution to complete the workflow of cell separation and...
Introducing RareCyte Orion, integrating Spatial Biology with Multiplex Imaging
Sep 13, 2022
Orion, the highly multiplexed fluorescent imaging system, empower investigators to unlock spatial context for key...
May 18, 2016
With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.
Related technologies: HTP Screening
Get more info
Brand profile
IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.
More info at:
www.intellicyt.com/
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
